STOCK TITAN
  1. Home
  2. News
  3. ICPT

Intercept Pharmaceuticals Inc - ICPT STOCK NEWS

Welcome to our dedicated news page for Intercept Pharmaceuticals (Ticker: ICPT), a resource for investors and traders seeking the latest updates and insights on Intercept Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Intercept Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Intercept Pharmaceuticals's position in the market.

News
Intercept Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Updates
Rhea-AI Summary
Intercept Pharmaceuticals reports Q2 2023 financial results with net sales of $83.7 million, representing 17% growth YoY. The company updates its full-year 2023 net sales guidance to $320-$340 million. Intercept expects to achieve meaningful profitability in 2024. The OCA-bezafibrate combination program shows positive results in Phase 2 studies for the treatment of PBC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.9%
Tags
earnings
-
News
Intercept to Announce Second Quarter 2023 Financial Results on August 2, 2023
Rhea-AI Summary
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) to announce Q2 2023 financial results on August 2, 2023, with a conference call and webcast. Participants can access the live webcast on the company's investor page and register to ask questions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
earnings
-
News
Intercept Announces Restructuring to Strengthen Focus on Rare and Serious Liver Diseases and Significantly Reduce Operating Expenses
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
none
News
Intercept Presents New Data Showing Significant Impact of OCA-bezafibrate Combination on Normalization of Multiple Biomarkers of PBC-Induced Liver Damage
Rhea-AI Summary
Intercept Pharmaceuticals announced new results from a planned interim analysis of its Phase 2 study assessing improvements in serum biomarkers of hepatic function, cholestasis, and inflammation in patients with primary biliary cholangitis (PBC) after treatment with a combination of obeticholic acid (OCA) and bezafibrate. The combination was effective in normalizing multiple biochemical markers associated with PBC-induced liver damage.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
none
-
News
Intercept Receives Complete Response Letter from FDA for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
none
-
News
Intercept Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC to be Featured in Podium Presentation at EASL Congress 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.84%
Tags
none
News
Intercept Pharmaceuticals to Conduct One-on-One Meetings with Investors at the Jefferies Healthcare Conference June 7-8, 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.14%
Tags
none
-
News
Intercept Announces Outcome of FDA Advisory Committee Meeting for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH
Rhea-AI Summary
Intercept Pharmaceuticals received disappointing outcome from the FDA Gastrointestinal Drugs Advisory Committee Meeting regarding the approval of obeticholic acid (OCA) for the treatment of pre-cirrhotic fibrosis due to NASH. Twelve out of 16 voting-eligible members voted against the benefits of OCA, while 15 members voted to defer approval until clinical outcome data from trial 747-303 are submitted and reviewed. Intercept will host a conference call on May 22, 2023, to discuss the meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Intercept Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Review Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH
Rhea-AI Summary
Intercept Pharmaceuticals, Inc. announces trading halt as FDA's Gastrointestinal Drugs Advisory Committee reviews obeticholic acid as a treatment for pre-cirrhotic fibrosis due to NASH. FDA's target action date is June 22, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Intercept Pharmaceuticals Receives FDA Orphan Drug Designation for the Fixed-Dose Combination of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis (PBC)
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.68%
Tags
clinical trial
Stock ICPT logo
Intercept Pharmaceuticals Inc

Nasdaq:ICPT

ICPT Rankings

N/A Ranked by Market Cap
#562 Ranked by Stock Gains
N/A Ranked by Dividends

ICPT Stock Data

794.69M
34.49M
3.13%
81.3%
24.24%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Morristown

About ICPT

we are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (pbc), nonalcoholic steatohepatitis (nash), primary sclerosing cholangitis (psc) and biliary atresia. in a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. we are committed to improving patients’ lives and addressing the liver community’s most pressing needs. our corporate headquarters is located in new york, and we have additional offices in san diego, london and perugia. for more information about intercept, please visit our website at: www.interceptpharma.com and follow us on twitter at: @interceptpharma.